The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China …

L Xu, H Chen, J Chen, M Han, H Huang, Y Lai… - Journal of hematology & …, 2018 - Springer
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used to treat
malignant hematological neoplasms and non-malignant hematological disorders …

Modern approaches to HLA-haploidentical blood or marrow transplantation

CG Kanakry, EJ Fuchs, L Luznik - Nature reviews Clinical oncology, 2016 - nature.com
Allogeneic blood or bone-marrow transplantation (alloBMT) is a potentially curative
treatment for a variety of haematological malignancies and nonmalignant diseases …

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

SO Ciurea, MJ Zhang, AA Bacigalupo… - Blood, The Journal …, 2015 - ashpublications.org
We studied adults with acute myeloid leukemia (AML) after haploidentical (n= 192) and 8/8
HLA-matched unrelated donor (n= 1982) transplantation. Haploidentical recipients received …

Who is the best donor for a related HLA haplotype-mismatched transplant?

Y Wang, YJ Chang, LP Xu, KY Liu… - Blood, The Journal …, 2014 - ashpublications.org
The best donor for a related donor for a human leukocyte antigen (HLA) haplotype-
mismatched transplant for hematological neoplasms is controversial. We studied outcomes …

Long‐term follow‐up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at …

Y Wang, DH Liu, KY Liu, LP Xu, XH Zhang, W Han… - Cancer, 2013 - Wiley Online Library
BACKGROUND: Many patients who require allogeneic hematopoietic stem cell
transplantation (allo‐HSCT) lack a human leukocyte antigen (HLA)‐matched donor …

T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT

Y Luo, H Xiao, X Lai, J Shi, Y Tan, J He… - Blood, The Journal …, 2014 - ashpublications.org
We developed an approach of T-cell-replete haploidentical hematopoietic stem cell
transplantation (HSCT) with low-dose anti-T-lymphocyte globulin and prospectively …

Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist

N Kekre, JH Antin - Blood, The Journal of the American Society …, 2014 - ashpublications.org
Most patients who require allogeneic stem cell transplantation do not have a matched
sibling donor, and many patients do not have a matched unrelated donor. In an effort to …

Haploidentical, unmanipulated, G-CSF–primed bone marrow transplantation for patients with high-risk hematologic malignancies

P Di Bartolomeo, S Santarone… - Blood, The Journal …, 2013 - ashpublications.org
Eighty patients with high-risk hematologic malignancies underwent unmanipulated, G-CSF–
primed BM transplantation from an haploidentical family donor. Patients were transplanted …

Integrating CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-cell …

YL Zhao, DY Liu, RJ Sun, JP Zhang, JR Zhou… - Frontiers in …, 2021 - frontiersin.org
Patients often undergo consolidation allogeneic hematopoietic stem cell transplantation
(allo-HSCT) to maintain long-term remission following chimeric antigen receptor (CAR) T …

[HTML][HTML] Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative …

N Cieri, R Greco, L Crucitti, M Morelli, F Giglio… - Biology of Blood and …, 2015 - Elsevier
Haploidentical hematopoietic stem cell transplantation (HSCT) performed using bone
marrow (BM) grafts and post-transplantation cyclophosphamide (PTCy) has gained much …